Review



p63  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Proteintech p63
    Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers (CK7, Napsin A and TTF1 for adenocarcinoma, CK5 and <t>P63</t> for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.
    P63, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 56 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p63/product/Proteintech
    Average 95 stars, based on 56 article reviews
    p63 - by Bioz Stars, 2026-02
    95/100 stars

    Images

    1) Product Images from "Probiotic-inspired hybrid nanovesicles for enhancing immune checkpoint therapy efficiency via tumor immune microenvironment modulation"

    Article Title: Probiotic-inspired hybrid nanovesicles for enhancing immune checkpoint therapy efficiency via tumor immune microenvironment modulation

    Journal: Bioactive Materials

    doi: 10.1016/j.bioactmat.2025.10.012

    Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers (CK7, Napsin A and TTF1 for adenocarcinoma, CK5 and P63 for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.
    Figure Legend Snippet: Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers (CK7, Napsin A and TTF1 for adenocarcinoma, CK5 and P63 for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.

    Techniques Used: Activity Assay, Ex Vivo, Staining, Derivative Assay, Expressing, Co-Culture Assay



    Similar Products

    human p63/tp73l antibody  (Bio-Techne corporation)
    94
    Bio-Techne corporation human p63/tp73l antibody
    Human P63/Tp73l Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human p63/tp73l antibody/product/Bio-Techne corporation
    Average 94 stars, based on 1 article reviews
    human p63/tp73l antibody - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    p63  (Akoya Biosciences)
    97
    Akoya Biosciences p63
    P63, supplied by Akoya Biosciences, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p63/product/Akoya Biosciences
    Average 97 stars, based on 1 article reviews
    p63 - by Bioz Stars, 2026-02
    97/100 stars
    		  Buy from Supplier
    p63  (Proteintech)
    95
    Proteintech p63
    Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers (CK7, Napsin A and TTF1 for adenocarcinoma, CK5 and <t>P63</t> for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.
    P63, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p63/product/Proteintech
    Average 95 stars, based on 1 article reviews
    p63 - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    il 17ra  (Biorbyt)
    93
    Biorbyt il 17ra
    Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers (CK7, Napsin A and TTF1 for adenocarcinoma, CK5 and <t>P63</t> for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.
    Il 17ra, supplied by Biorbyt, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/il 17ra/product/Biorbyt
    Average 93 stars, based on 1 article reviews
    il 17ra - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    il17 ra  (Biorbyt)
    93
    Biorbyt il17 ra
    Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers (CK7, Napsin A and TTF1 for adenocarcinoma, CK5 and <t>P63</t> for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.
    Il17 Ra, supplied by Biorbyt, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/il17 ra/product/Biorbyt
    Average 93 stars, based on 1 article reviews
    il17 ra - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    catalog no 12143 1 ap  (Proteintech)
    95
    Proteintech catalog no 12143 1 ap
    Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers (CK7, Napsin A and TTF1 for adenocarcinoma, CK5 and <t>P63</t> for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.
    Catalog No 12143 1 Ap, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/catalog no 12143 1 ap/product/Proteintech
    Average 95 stars, based on 1 article reviews
    catalog no 12143 1 ap - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    trp63  (Proteintech)
    95
    Proteintech trp63
    Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers (CK7, Napsin A and TTF1 for adenocarcinoma, CK5 and <t>P63</t> for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.
    Trp63, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/trp63/product/Proteintech
    Average 95 stars, based on 1 article reviews
    trp63 - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers (CK7, Napsin A and TTF1 for adenocarcinoma, CK5 and P63 for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.

    Journal: Bioactive Materials

    Article Title: Probiotic-inspired hybrid nanovesicles for enhancing immune checkpoint therapy efficiency via tumor immune microenvironment modulation

    doi: 10.1016/j.bioactmat.2025.10.012

    Figure Lengend Snippet: Antitumor activity of ROMV/TMAO and CD8 + T cells infiltration in ex vivo human LCO models. ( A ) Schematic depicting the process of construction of human lung cancer organoids (LCOs) from patient tumors for the subsequent CD8 + T cells infiltration and anti-tumor effect in LCOs after different treatment. ( B ) H&E staining images of human lung cancer tissues (LCTs) and derived organoids. Scale bars, 100 μm. ( C ) IF images of human LCTs and human LCOs. The LCOs kept the tumor cell organizations and the expression patterns of the characteristic markers (CK7, Napsin A and TTF1 for adenocarcinoma, CK5 and P63 for squamous cell carcinoma) of LCTs. Red: markers. Blue: DAPI. Scale bars, 50 μm. ( D ) CD8 + T cells infiltration in human LCOs after different treatment. Red, anti-CD8α. Blue, DAPI. Scale bars, 40 μm. ( E to G ) Fluorescent images of LCOs from patient 100 (E), patient 102 (F) and patient 106 (G) showing the viability of organoids (green: live cells; red: dead cells) in LCOs + PBMC co-culture system after different treatment. Scale bars, 20 μm. The experiments are repeated three times. ( H ) Bright-field images of LCOs showing the size of organoids after different treatment. Scale bars, 100 μm. G1: PBS, G2: α-PD-L1, G3: ROMV/TMAO, G4: ROMV/TMAO + α-PD-L1.

    Article Snippet: The prepared sections were then stained with anti-CD8α (Abcam, ab237709), CK7 (Proteintech, 17513-1-AP), P63 (Proteintech, 12143-1-AP), Napsin A (ABclonal, A5594), CK5 (Proteintech, 28506-1-AP), and TTF1 (ABclonal, A18128).

    Techniques: Activity Assay, Ex Vivo, Staining, Derivative Assay, Expressing, Co-Culture Assay